Bionano Genomics Inc
For the period ended Dec 31, 2023. Filed Mar 5, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 5, 2024
BNGO$1.23+6.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
| Years Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Net Loss: | $(232,493,000) | $(132,596,000) |
| Other comprehensive income (loss): | ||
| Unrealized gain (loss) on investment securities | 1,082,000 | (548,000) |
| Foreign currency translation adjustments | 65,000 | (37,000) |
| Other comprehensive income (loss) | $1,147,000 | $(585,000) |
| Total comprehensive loss | $(231,346,000) | $(133,181,000) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.